KRSA — Korsana Biosciences, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1755237 ·
Last close
$32.50
Market Cap
$1.48B
52W High
$59.36
52W Low
$7.19
ADV30
170,978
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -48,274,000 | -46,425,000 | 462,084,000 | 456,221,000 | 70,521,000 |
| Jun 2026 | — | — | — | — | — | — | — |
| Dec 2025 | 0 | — | -14,969,000 | -13,694,000 | 154,596,000 | 154,135,000 | 188,564,000 |
| Sep 2025 | 0 | — | -21,957,000 | -21,723,000 | — | — | — |
Balance + Analyst (yfinance extras)
Retained Earnings
—
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
5
Annual Trend (SEC EDGAR, last 2y)
Revenues vs Net Income (last 2y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -37,291,000 | -35,642,000 | 154,596,000 | 188,564,000 | -33,968,000 | -22,406,000 |
| Dec 2024 | 0 | -109,000 | -88,000 | 10,108,000 | 10,042,000 | 66,000 | 44,000 |
TTM Snapshot
Revenues TTM
$1,900,000
NetIncome TTM
$-6,707,000
OpCashFlow TTM
—
Assets (Latest)
$6,930,000
Forward EPS
$-3.56
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| URGN | UroGen Pharma Ltd. | $1.47B | $29.87 | — |
| QURE | uniQure N.V. | $1.46B | $20.78 | — |
| PCRX | Pacira BioSciences, Inc. | $1.46B | $36.48 | — |
| ADRX | ADARx Pharmaceuticals, Inc. | $1.53B | $13.82 | — |
| PGEN | PRECIGEN, INC. | $1.54B | $4.29 | — |
News headlines (Yahoo Finance, 1h cache)
Korsana Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Update
2026-11-05 12:00 · Yahoo
Korsana Biosciences to Participate in Upcoming Investor Conferences
2026-11-02 21:05 · Yahoo
Can Tenet Healthcare Beat Q3 Earnings on Ambulatory Care Strength?
2026-10-27 15:56 · Yahoo
Korsana Biosciences (KRSA) At $31.20 Leaves Valuation Questions On A Sharp 2026 Run
2026-10-02 12:06 · Yahoo
Korsana Biosciences Completes Closing of Merger with Cyclerion Therapeutics and Previously Announced Private Placement of $380 Million
2026-09-08 20:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.